Current Event 

Overview
Conference A
Conference B 
Pre-Conference Workshop
Speakers
PDF Download
Press Pass 
Request Brochure 

Covance

phadia

GYROS

ICON Develoment Solutions

International Drug Discovery

Biolexis

BioPharm

BioProcess

CanBiotech

Current Immunology Reviews

Drug Discovery News

Expert Review of Vaccines

GenomeWeb

PharmaVoice

PharmCast

Science AAAS

SelectScience

The Scientist

MONDAY, OCTOBER 26

Pre-conference workshop

Technical Advice on Assay Development, Validation and Sample Analysis

Course Leaders:

Boris Gorovits, Ph.D., Director, Bioanalytical R&D, Wyeth and

Ana Menendez, Ph.D., Senior Director Biotechnology, Catalent Pharma Solutions

8:00am Workshop Registration

8:30am – 12:30pm

An interactive workshop to enable attendees to work out an immunogenicity
pre-clinical and clinical testing protocol for their particular therapeutic protein. Recent advances will be presented and areas of difficulty will be addressed. Delegates are encouraged to contribute with their own experiences and to
bring questions for discussion.

The following topics will be covered:

Immunogenicity risk assessment

  • The immune response and the nature of antibodies
  • Classification of biological drugs into distinct risk categories
  • Role of neutralizing antibodies
  • Determination of the immunogenicity risks for a given biological

Measurement of immunogenicity

  • Screening
  • Confirmation
  • Neutralization
  • Characterization

Assay methodologies and comparison of the methods

  • ELISA
  • Surface Plasmon Resonance
  • Electrochemiluminescence
  • Cell-based assays

Critical issues in assay validation

  • Guidelines and White paper recommendations on validation strategy
  • Assay cutpoint determination
  • Problems to anticipate
  • Low-affinity antibodies: what is their significance from a clinical point of view and how do you deal with them?
  • How is validation done without a specific positive control?
  • How do you deal with interfering drug?
  • Other factors which can cause interference
  • Positive controls and assay sensitivity
  • Interpretation of results

Development of cell-based neutralizing antibody (Nab) assays

  • Emerging trends in the development of Nab assays
  • Clinical implementation of an established Nab assay

Application step to discuss sample analysis and any relevant issues

  • Practical exercises

Discussion, questions and answers

 


For more information, please contact:
Nicole Lyscom, Ph.D.
Conference Producer
Cambridge Healthtech Institute (CHI)
Phone: +44-1483-826359
E-mail: nlyscom@healthtech.com

For sponsorship information, please contact:
Ilana Quigley
Manager, Business Development
Cambridge Healthtech Institute (CHI)
Phone:  +1-781-978-5457
Cell:  +1-857-636-2334
Email:  iquigley@healthtech.com